GLAND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,825 INR | +0.41% |
|
+0.49% | -5.18% |
| Jun. 20 | Fosun Pharma Trims Stake in Gland Pharma to 51.83% | MT |
| Jun. 18 | Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million | CI |
Valuation
| Fiscal Period: Marzo | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 405,432 | 537,705 | 208,882 | 300,647 | - | - |
| Enterprise Value (EV) 1 | 375,414 | 506,809 | 171,208 | 288,736 | 282,197 | 271,022 |
| P/E ratio | 39.3 x | 44.4 x | 26.7 x | 39.4 x | 31.1 x | 24.3 x |
| Yield | - | - | - | 1.08% | 0.13% | 0.13% |
| Capitalization / Revenue | 11.7 x | 12.2 x | 5.76 x | 5.37 x | 4.69 x | 4.22 x |
| EV / Revenue | 10.8 x | 11.5 x | 4.72 x | 5.1 x | 4.4 x | 3.8 x |
| EV / EBITDA | 28.8 x | 33.6 x | 16.7 x | 21.7 x | 17.8 x | 14.5 x |
| EV / FCF | 99.8 x | 181 x | 120 x | 47.6 x | -159 x | 41.3 x |
| FCF Yield | 1% | 0.55% | 0.84% | 2.1% | -0.63% | 2.42% |
| Price to Book | 6.51 x | 7.48 x | 2.62 x | 3.48 x | 3.13 x | 2.8 x |
| Nbr of stocks (in thousands) | 163,593 | 164,303 | 164,701 | 164,752 | - | - |
| Reference price 2 | 2,478 | 3,273 | 1,268 | 1,817 | 1,817 | 1,817 |
| Announcement Date | 5/17/21 | 5/19/22 | 5/18/23 | 5/22/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 26,332 | 34,629 | 44,007 | 36,246 | 56,647 | 64,154 | 71,299 |
| EBITDA 1 | - | 13,022 | 15,102 | 10,248 | 13,331 | 15,860 | 18,722 |
| EBIT 1 | - | 12,034 | 13,999 | 8,780 | 9,885 | 12,015 | 14,824 |
| Operating Margin | - | 34.75% | 31.81% | 24.22% | 17.45% | 18.73% | 20.79% |
| Earnings before Tax (EBT) 1 | - | 13,348 | 16,186 | 10,546 | 11,325 | 13,610 | 16,160 |
| Net income 1 | - | 9,970 | 12,117 | 7,810 | 7,725 | 9,616 | 12,277 |
| Net margin | - | 28.79% | 27.53% | 21.55% | 13.64% | 14.99% | 17.22% |
| EPS 2 | - | 62.99 | 73.64 | 47.43 | 46.89 | 58.39 | 74.65 |
| Free Cash Flow 1 | - | 3,762 | 2,800 | 1,430 | 6,069 | -1,776 | 6,564 |
| FCF margin | - | 10.86% | 6.36% | 3.95% | 10.71% | -2.77% | 9.21% |
| FCF Conversion (EBITDA) | - | 28.89% | 18.54% | 13.96% | 45.52% | - | 35.06% |
| FCF Conversion (Net income) | - | 37.73% | 23.11% | 18.31% | 78.56% | - | 53.47% |
| Dividend per Share 2 | - | - | - | - | 20.00 | 2.333 | 2.333 |
| Announcement Date | 7/10/20 | 5/17/21 | 5/19/22 | 5/18/23 | 5/22/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,877 | 11,539 | 10,805 | 10,633 | 11,030 | 8,569 | 10,444 | 9,383 | 7,850 | 12,087 | 13,439 | 14,508 | 15,710 | 15,469 |
| EBITDA 1 | 3,277 | 4,363 | 3,766 | 3,489 | 3,484 | 2,699 | 2,969 | 2,896 | 1,684 | 2,982 | 3,128 | 3,600 | 3,708 | - |
| EBIT 1 | 3,028 | 4,110 | 3,505 | 3,211 | 3,173 | 2,350 | 2,602 | 2,520 | 1,309 | 2,286 | 2,299 | 2,769 | 2,734 | 2,746 |
| Operating Margin | 34.1% | 35.62% | 32.44% | 30.2% | 28.77% | 27.43% | 24.91% | 26.85% | 16.67% | 18.92% | 17.11% | 19.09% | 17.4% | 17.75% |
| Earnings before Tax (EBT) 1 | 3,489 | 4,718 | 4,007 | 3,656 | 3,805 | 3,085 | 3,241 | 3,108 | 1,112 | 2,613 | 2,828 | 3,354 | 3,302 | - |
| Net income 1 | 2,604 | 3,507 | 3,021 | 2,730 | 2,859 | 2,292 | 2,412 | 2,319 | 786.8 | 1,941 | 2,161 | 2,332 | 2,336 | - |
| Net margin | 29.33% | 30.39% | 27.96% | 25.68% | 25.92% | 26.74% | 23.1% | 24.72% | 10.02% | 16.06% | 16.08% | 16.07% | 14.87% | - |
| EPS 2 | - | 21.37 | 18.37 | 16.62 | 17.36 | 13.92 | 14.65 | 14.08 | 4.780 | 11.78 | 12.70 | 13.60 | 14.23 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/17/21 | 7/21/21 | 10/22/21 | 1/21/22 | 5/19/22 | 7/20/22 | 10/26/22 | 1/23/23 | 5/18/23 | 8/7/23 | - | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 30,018 | 30,896 | 37,674 | 15,197 | 18,450 | 29,626 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 3,762 | 2,800 | 1,430 | 6,069 | -1,776 | 6,564 |
| ROE (net income / shareholders' equity) | - | 20.9% | 18.6% | 10.3% | 9.26% | 10.6% | 11.8% |
| ROA (Net income/ Total Assets) | - | 18.8% | 16.9% | 9.4% | 7.95% | 8.3% | 10.2% |
| Assets 1 | - | 52,911 | 71,651 | 83,056 | 97,194 | 115,854 | 120,365 |
| Book Value Per Share 2 | - | 381.0 | 438.0 | 483.0 | 530.0 | 580.0 | 649.0 |
| Cash Flow per Share 2 | - | - | - | 22.10 | 60.50 | 61.80 | - |
| Capex 1 | - | 2,288 | 5,113 | 2,209 | 3,899 | 5,012 | 3,286 |
| Capex / Sales | - | 6.61% | 11.62% | 6.1% | 6.88% | 7.81% | 4.61% |
| Announcement Date | 7/10/20 | 5/17/21 | 5/19/22 | 5/18/23 | 5/22/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,817
INR
Average target price
1,827
INR
Spread / Average Target
+0.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.18% | 3.59B | |
| +56.75% | 819B | |
| -6.82% | 351B | |
| +19.63% | 329B | |
| +9.22% | 298B | |
| +17.42% | 242B | |
| +2.33% | 225B | |
| +13.48% | 217B | |
| +9.59% | 168B | |
| -2.81% | 158B |
- Stock Market
- Equities
- GLAND Stock
- Financials Gland Pharma Limited
